[Federal Register Volume 77, Number 76 (Thursday, April 19, 2012)]
[Notices]
[Pages 23485-23486]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-9418]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA 2012-N-0001]
Food and Drug Administration Patient Network Annual Meeting;
Input Into Food and Drug Administration Benefit-Risk Decisionmaking:
Opportunities and Challenges; Hosted by the Food and Drug
Administration Office of Special Health Issues; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing a meeting for
patients, caregivers, independent patient advocates and patient
advocate groups, and health professional groups to explore ways to more
effectively include patient input in regulatory decisionmaking on drug,
device, and biological products. The meeting will serve as a forum for
FDA's patient stakeholders and the general public, including health
professionals, academia, and industry to learn about the regulatory
process related to the medical product life cycle, analyze where in the
process patient input may be most practical and most valuable, and
explore practicable approaches to collecting and incorporating
meaningful input that well represents broad patient perspectives into
regulatory decisions.
DATES: Date and Time: The meeting will be held on May 18, 2012, from 9
a.m. to 4:30 p.m. Register at http://fda.contractmeetings.com/home on
or before May 4, 2012. Please include the name and title of the person
attending, the name of the organization, the role within the
organization, email address, and telephone number. There is no
registration fee for this conference. Early registration is suggested
because space is limited. We request that organizations limit the
number of representatives to two. For further registration information
or problems with the Web site, call Cindy de Sales, 1-240-316-3200,
ext. 207.
If you need special accommodations due to a disability, please
contact Steve Morin at least 7 days in advance.
Location: The meeting will be held at the FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room
(Rm. 1503) Silver Spring, MD 20993.
Contact Person: Steve Morin, Office of Special Health Issues, 10903
New Hampshire Ave., Silver Spring, MD 20993, 301-796-0161, FAX: 301-
847-8623, [email protected].
SUPPLEMENTARY INFORMATION:
I. FDA Patient Network
This is the inaugural FDA Patient Network Annual Meeting hosted by
the FDA Office of Special Health Issues, the Agency's liaison to the
patient and health professional communities. This annual meeting is
being hosted in conjunction with the launch of the overarching FDA
Patient Network program. The FDA Patient Network is a new resource for
patients, caregivers, independent patient advocates, and patient
advocate groups that seek to:
Educate and inform patient stakeholders about FDA, its
regulatory
[[Page 23486]]
authorities and processes, its initiatives and programs, etc.; and,
Provide a venue for advocacy for patient stakeholders
within FDA and be transparent to patients about Agency actions.
In addition to an annual meeting, the FDA Patient Network consists
of other activities, including the:
FDA Patient Network Web site--A new, patient-centered Web
site that contains educational modules, centralized Agency information,
and multidirectional communication tools;
Biweekly FDA Patient Network News email newsletter; and
hosting of periodic meetings, briefings, and listening session between
patient advocates and FDA staff.
II. Patient Perspectives in Regulatory Decisionmaking
Establishing a means for obtaining input from patients and patient
advocate groups will allow FDA to further enhance its benefit-risk
assessment in regulatory decisionmaking. Patients who live with a
disease have a direct stake in the outcomes of the review process and
are in a unique position to contribute to the weighing of benefit-risk
considerations that can occur throughout the medical product
development process. Though several programs exist that facilitate
patient representation on Advisory Committees or participation in
selected review meetings, there are currently few venues in which the
patient perspective is discussed outside of a specific product's
marketing application review. The medical product review process could
benefit from a more scientific, systematic, and expansive approach to
obtaining input from patients who are experiencing a particular disease
condition.
As part of the proposed agreements for Prescription Drug User Fee
Act (PDUFA) V, FDA plans to conduct meetings with patients and patient
advocacy groups to gather broader patient input. This meeting kicks off
these efforts and provides an opportunity to gain feedback on how FDA
can best structure these upcoming meetings.
FDA seeks public discussion based on the following questions. These
questions are intended to frame patient input at the May 18, 2012,
meeting and there will be time at the meeting to discuss the following
issues.
(1) How can FDA ensure gathering a broad range of representative
patient input that is relevant to a specific disease area during its
meetings with patients? For example, who should serve as
representatives of patients?
(2) What methodological and practical issues should FDA consider as
it develops its strategy for eliciting the patient perspective? For
instance, FDA is interested in addressing topics including, but not
limited to, the following:
(a) Are there particular advantages or disadvantages to utilizing
face-to-face meetings versus web-based or other methods in obtaining
the patient perspective on a particular disease condition and its
treatment?
(b) How can FDA ensure that certain subpopulations, such as
patients with the most severe form of the disease, are represented?
III. Center for Drug Evaluation and Research and Center for Biologics
Evaluation and Research Efforts
Center for Drug Evaluation and Research and Center for Biologics
Evaluation and Research plan to conduct a series of patient-focused
drug development meetings to gather patient input on the clinical
context of a disease and its impact on a patient's daily life. These
considerations, which would include an analysis of the severity of the
disease condition and the current state of the available treatment
options, can be critical in regulatory decisionmaking. FDA is
interested in obtaining patient input on the context of specific
disease areas through the patient-focused drug development meetings.
The following questions are examples of topics for which FDA believes
the patient perspective could add valuable insight. They are presented
in this document for general discussion at the Patient Network
Conference.
A. Understanding the Disease Condition
(1) What are the clinical manifestations of the disease that have
the greatest impact on patients?
(2) Are there other aspects of the disease that have a significant
impact on a patient's daily life? (e.g., impaired mobility, sleep
problems, etc.)
(3) How do the clinical manifestations change with disease
progression?
(4) How do the other aspects of the disease change with disease
progression?
B. Assessment of Treatment Options
(1) How effective are approved therapies at treating the clinical
manifestations of the disease?
(2) How well do approved therapies mitigate the other aspects of
the disease?
(3) How does the effectiveness of approved therapies change with
progression of the disease?
(4) Does therapy effectiveness vary by patient subpopulation?
FDA is continuing to make plans for its efforts and will be able to
provide more detail on the patient-focused drug development meetings at
the Patient Network Conference.
IV. Center for Devices and Radiologic Health Efforts
Center for Devices and Radiologic Health is interested in a public
discussion on issues related to risk associated with medical products,
and on avenues for patients to provide input into regulatory
decisionmaking related to the amount of risk patients may be willing to
accept in exchange for a potential treatment benefit. The following
questions are presented in this document for general discussion at the
Patient Network Conference.
(1) How do patients perceive and weigh risks associated with
medical treatment in light of the risk associated with the underlying
condition being treated and the potential benefit from the treatment?
(2) Under what circumstances and in which populations would various
levels of risk be appropriate/acceptable?
(3) How can medical device companies, government, academia,
community physicians and patients collaborate to account for the level
of risk acceptable to patients affected by serious or life threatening
illnesses?
(4) What mechanisms would be appropriate for patients to provide
input into regulatory decisionmaking for new therapeutic and diagnostic
products--e.g., web-based survey instruments? Patient representation at
advisory committee meetings? Patient input to medical device companies
during clinical trial design? Who (FDA, patient advocate groups,
medical device companies, etc.) could sponsor such surveys?
(5) Are patients willing to accept responsibility for the level of
risk to which they may be exposed if patient input increases risk
tolerance?
Dated: April 13, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-9418 Filed 4-18-12; 8:45 am]
BILLING CODE 4160-01-P